- Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced it has been awarded a grant from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes (T1D) research and advocacy organization, through its Industry Discovery and Development Partnership (IDDP) program, to support the ongoing INHALE-1ST clinical study evaluating the initiation of Afrezza® (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients.
The INHALE-1ST study is a multi-center clinical trial designed to assess the safety and efficacy of Afrezza used in combination with subcutaneously injected basal insulin once-daily in youth aged 10 to